INCY · 10-Q · 2026Q3 · Full report

CMS Medicaid Rebate Litigation Settlement

INCYTE CORP · 2026-10-29 · Importance 53 · Surprise 60 · Matches filing data

Incyte sued CMS over its regulation defining a “line extension” under the Medicaid rebate program, arguing that it improperly treated OPZELURA as a line extension of JAKAFI. Under a second-quarter 2026 agreement, CMS will not apply the regulation to OPZELURA as if it were a JAKAFI line extension. Incyte recorded a one-time, non-cash $246.0 million net-sales benefit in the second quarter from reversing previously accrued liabilities through March 31, 2026, and expects improved OPZELURA gross-to-net results going forward.

Key facts

• In the second quarter of 2026, Incyte recorded a one-time, non-cash $246.0 million benefit in net sales from reversing previously established accrual balances through March 31, 2026 related to potential application of the line extension regulations to OPZELURA. source
• Incyte will no longer accrue for potential application of the line extension regulations to OPZELURA and expects an improvement to OPZELURA's gross-to-net on a go-forward basis. source
• CMS agreed in the second quarter of 2026 not to apply the Medicaid line extension regulation to OPZELURA as if it were a line extension of JAKAFI. source

Impact estimates